Patricia Mercier-Letondal1, Chrystel Marton2, Yann Godet2, Jeanne Galaine2,3. 1. Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098 RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, 25000, Besançon, France. patricia.letondal@efs.sante.fr. 2. Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098 RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, 25000, Besançon, France. 3. Etablissement Français du Sang Bourgogne Franche-Comté, Activité Médicaments de Thérapie Innovante, 25000, Besançon, France.
Abstract
BACKGROUND: Metabolic cell features are able to give reliable information on cell functional state. Thus, metabolic potential assessment of T cells in malignancy setting represents a promising area, especially in adoptive cell therapy procedures. Easy to set up and convenient Seahorse technology have recently been proposed by Agilent Technologies and it could be used to monitor T cells metabolic potential. However, this method demonstrates an inter-assay variability and lacks practices standardization. RESULTS: We aimed to overcome these shortcomings thanks to a lymphoblastic derived JURKAT cell line seeding in each experiment to standardize the Seahorse process. We used an adapted XF Cell MitoStress Kit protocol, consisting in the evaluation of basal, stressed and maximal glycolysis and oxidative phosphorylation related parameters, through sequential addition of oligomycin and carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) to a glucose containing medium. Data were acquired and analyzed through Agilent Seahorse XFe96 analyzer. Indeed, we validated this method in the light of ICH Q2 (R1) guidelines. We were able to confirm the specificity and accuracy of the method. We also demonstrated the precision, linearity and range of the method in our experimental conditions. CONCLUSION: The validation of the method consisting in a JURKAT cell line experimental incorporation as a control material contributes to improve the Seahorse technology's robustness. These results lay the groundwork for the implementation of this technology to optimize T cell based cellular therapy products production process and monitoring.
BACKGROUND: Metabolic cell features are able to give reliable information on cell functional state. Thus, metabolic potential assessment of T cells in malignancy setting represents a promising area, especially in adoptive cell therapy procedures. Easy to set up and convenient Seahorse technology have recently been proposed by Agilent Technologies and it could be used to monitor T cells metabolic potential. However, this method demonstrates an inter-assay variability and lacks practices standardization. RESULTS: We aimed to overcome these shortcomings thanks to a lymphoblastic derived JURKAT cell line seeding in each experiment to standardize the Seahorse process. We used an adapted XF Cell MitoStress Kit protocol, consisting in the evaluation of basal, stressed and maximal glycolysis and oxidative phosphorylation related parameters, through sequential addition of oligomycin and carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) to a glucose containing medium. Data were acquired and analyzed through Agilent Seahorse XFe96 analyzer. Indeed, we validated this method in the light of ICH Q2 (R1) guidelines. We were able to confirm the specificity and accuracy of the method. We also demonstrated the precision, linearity and range of the method in our experimental conditions. CONCLUSION: The validation of the method consisting in a JURKAT cell line experimental incorporation as a control material contributes to improve the Seahorse technology's robustness. These results lay the groundwork for the implementation of this technology to optimize T cell based cellular therapy products production process and monitoring.
Entities:
Keywords:
Control material; T cell based immunotherapies; T cell metabolic potential
Authors: Ajit S Divakaruni; Alexander Paradyse; David A Ferrick; Anne N Murphy; Martin Jastroch Journal: Methods Enzymol Date: 2014 Impact factor: 1.600
Authors: Sara Bruzzaniti; Marialuisa Bocchino; Marianna Santopaolo; Gaetano Calì; Anna Agnese Stanziola; Maria D'Amato; Antonella Esposito; Enrica Barra; Federica Garziano; Teresa Micillo; Candida Zuchegna; Antonella Romano; Salvatore De Simone; Bruno Zuccarelli; Maria Mottola; Veronica De Rosa; Antonio Porcellini; Francesco Perna; Giuseppe Matarese; Mario Galgani Journal: Proc Natl Acad Sci U S A Date: 2019-07-15 Impact factor: 11.205
Authors: Alex Cordero; Deepak Kanojia; Jason Miska; Wojciech K Panek; Annie Xiao; Yu Han; Nicolas Bonamici; Weidong Zhou; Ting Xiao; Meijing Wu; Atique U Ahmed; Maciej S Lesniak Journal: Oncogene Date: 2019-07-19 Impact factor: 9.867